Ulf Wiinberg appointed new CEO of Lundbeck

Ulf Wiinberg appointed new CEO of Lundbeck


The Supervisory Board of H. Lundbeck A/S has today appointed Ulf Wiinberg as new president and CEO of Lundbeck. Ulf Wiinberg will take up his new position on 1 June 2008.
"I am very pleased to announce that Ulf Wiinberg will join Lundbeck as president and CEO," says Per Wold-Olsen, Chairman of Lundbeck's Supervisory Board.
Ulf Wiinberg will be leaving the US pharmaceutical company Wyeth, where he has been responsible for two areas: Strategic oversight of Wyeth's biopharma activities and as President of Wyeth Europe, Middle East, Africa and Canada - the latter division generates revenues of approximately DKK 30 billion (USD 6 billion) and employs 5,200 people.
Lundbeck's future president and CEO started his pharmaceutical career in Sweden in 1981 and has worked for Wyeth for 27 years, where he has held management positions in Europe as well as in the USA. Ulf Wiinberg distinguishes himself by his strong commercial competencies and has achieved a number of significant results at Wyeth.
"Ulf Wiinberg is uniquely qualified to handle the challenges that Lundbeck faces in the short term, and with his broad experience he can contribute to meeting the strategic challenges that we face in the long term," says Per Wold-Olsen.
Ulf Wiinberg was previously responsible for Wyeth Consumer Healthcare Products and Managing Director of Wyeth in the UK. Ulf Wiinberg has served as a member of Wyeth's management committee as well as of the corporation's operations committee, legal committee and HR committee.
Ulf Wiinberg is 49 years old, married and has four children. He is a Danish citizen who was born and raised in Sweden, and has lived and worked for five years in the UK and 13 years in the USA. In connection with his new position, Ulf Wiinberg will move to Denmark from New Jersey, USA.
"Lundbeck is a very interesting company with a focused strategy within diseases of the central nervous system. It is an area where there unfortunately is a vast need for innovation and progress in the treatment of a number of diseases, as many patients do not currently have access to adequate treatment," says Ulf Wiinberg.
"As a previous competitor I know that Lundbeck has a good reputation and is acknowledged as company with great strengths within research and development and for being very good at sales and marketing. I am convinced that the energy and competency within the company will enable us to set new standards for patients and for Lundbeck," says Ulf Wiinberg.
There will be a press conference at Lundbeck's address above on 29 April at 2pm. Journalists and capital market stakeholders are welcome. The meeting will be conducted in English.
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Jens Højbjerg
Director Media Relations Manager
+45 36 43 30 79 +45 36 43 28 33
Palle Holm Olesen  
Head of Investor Relations  
+45 36 43 24 26  

Stock Exchange Release No 337 - 29 April 2008
About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2007, the company's revenue was DKK 11 billion (approximately EUR 1.5 billion or USD 2.0 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.